We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current 0LB2 market cap is 3B. The company's latest EPS is USD 0.0241 and P/E is 1485.06.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 392.76M | 520.4M | 586.31M | 667.75M | 609.04M |
| Operating Income | 148.57M | 173.7M | 86.03M | 46.12M | -5.27M |
| Net Income | 113.06M | 126.95M | 53.42M | 60.71M | 1.32M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 1.16B | 1.5B | 1.69B | 1.7B | 1.28B |
| Total Liabilities | 564.85M | 759.24M | 873.3M | 816.3M | 356.16M |
| Total Equity | 595.43M | 744.86M | 815.85M | 886.2M | 921.52M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 143.13M | 138.4M | 127.13M | 116.83M | 111.09M |
| Investing | -157.92M | -34.7M | -81.91M | -216.66M | 268.73M |
| Financing | 3.93M | 3.56M | -130.42M | -10.48M | -397.88M |
| Market Cap | 3B |
| Price to Earnings Ratio | 1485.06 |
| Price to Sales Ratio | 3.21 |
| Price to Cash Ratio | 26.05 |
| Price to Book Ratio | 2.12 |
| Dividend Yield | - |
| Shares Outstanding | 54.63M |
| Average Volume (1 week) | 1.28k |
| Average Volume (1 Month) | 483 |
| 52 Week Change | 0.00% |
| 52 Week High | 55.00 |
| 52 Week Low | 55.00 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Supernus Pharmaceuticals Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.supernus.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
